The US drug regulator has approved pafolacianine (Cytalux ), an imaging drug meant for helping surgeons in identifying ovarian cancer lesions. Indicated for use in adult patients with ovarian cancer to help identify cancerous lesions during surgery, pafolacianine is a diagnostic agent that is administered in the form of an intravenous injection prior to surgery. It improves the surgeon’s ability to locate additional ovarian cancerous tissue that is normally difficult to detect during surgery.